Biopharmaceutical company developing topical treatments for inflammatory dermatological conditions.
Arcutis Biotherapeutics, Inc. is a pioneering biopharmaceutical firm specializing in the development and commercialization of innovative treatments for dermatological diseases. Founded in 2016 and based in Westlake Village, California, the company is dedicated to addressing critical unmet needs in dermatology through advanced therapeutic solutions.
At the forefront of Arcutis Biotherapeutics' portfolio is ARQ-151, a topical cream formulation of roflumilast. This lead product candidate has successfully completed Phase III clinical trials for both plaque psoriasis and atopic dermatitis, showcasing its potential to significantly improve patient outcomes in these conditions.
The company's robust pipeline includes ARQ-154, a topical foam formulation of roflumilast targeting seborrheic dermatitis and scalp psoriasis. Additionally, Arcutis Biotherapeutics is developing ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo, and ARQ-255, a specialized formulation of ivarmacitinib designed to penetrate deeper into the skin to treat alopecia areata effectively. The pipeline further extends to ARQ-234, a CD200R fusion protein tailored for moderate-to-severe atopic dermatitis.
Renowned for its commitment to scientific innovation and patient-centric research, Arcutis Biotherapeutics continues to expand its impact in dermatology. By advancing a diverse portfolio of therapeutic candidates and leveraging strategic partnerships, the company aims to redefine treatment standards and enhance the quality of life for dermatology patients worldwide.